InvestSMART

Racura Oncology Ltd (ASX:RAC)

ALERT: Price-sensitive ASX Announcement for RAC
Current share price for RAC : $1.540 -0.53 (-25.60%)+
Announcement
Release
28 Jul 2026 9:12AM
Price at Release
$2.070
Full Release
download
Summary
Racura Oncology Ltd reported significant clinical and corporate advancements in its June 2026 Quarterly Activities Report. During the quarter, Racura progressed its clinical trials, notably the Phase 1 HARNESS-1 trial and the CPACS trial, supporting its lead compound RC220's safety and efficacy profiles. The company maintained a strong cash position of $34.3 million at the quarter's end, which is expected to fund activities into CY2028. Key developments included presenting preclinical data on RC220's mechanism at the AACR Annual Meeting and forming strategic financial agreements to raise $34.3 million since 2025. These efforts reinforce Racura's mission to develop innovative cancer therapies targeting MYC-driven oncology indications.
Key Points
  • Racura held $34.3 million in cash as of 30 June 2026.
  • First patient treated in HARNESS-1 trial for EGFR-mutated NSCLC.
  • Presented RC220 data at AACR 2026 Annual Meeting.
  • CPACS trial cleared to escalate to next RC220 dose level.
  • Raised $34.3 million since 2025 through various financial activities.
  • Strong clinical and financial progress reported for June quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.